10-K - AIM ImmunoTech Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

AIM ImmunoTech Inc. reported a net loss of $14.0 million for FY 2025, an improvement from a $17.3 million loss in FY 2024. Total revenues were minimal at $88K, derived solely from clinical treatment programs. The company incurred significant operating losses of $11.7 million, driven by high research and development ($3.9M) and general and administrative ($7.7M) expenses. Cash and cash equivalents stood at $3.0M, with total assets of $5.8M. The balance sheet shows a stockholders' deficit of $9.8M, and the company is not in compliance with NYSE American listing requirements, which mandate a minimum stockholders' equity of $6.0M. Management has submitted a plan to regain compliance by June 11, 2026.

Key Takeaways

1Net loss improved to $14.0M in FY 2025 from $17.3M in FY 2024.

2Total revenues were only $88K, all from clinical treatment programs.

3Stockholders' deficit was $9.8M, below the NYSE American minimum of $6.0M.

4Cash and cash equivalents were $3.0M as of December 31, 2025.

5Research and development expenses were $3.9M for the year.

Key Financial Metrics

EPS

-$9

-$31 prior year

Revenue

$88K

-48.2%

Net Income

-$14.0M

+19.4%